07 October 2021 | Thursday | News
Image Source : Public Domain
"Luciole aims to be the premier mitochondrial repair company by applying state-of-theart technology and an efficient, virtual company approach to developing novel medicines. We are pleased to be using Cyclica's first in class polypharmacology and AI enabled platform to efficiently identify new molecules with disease-modifying potential. The collaboration with Cyclica will jump start our drug discovery and development program to enable the acquisition of financial resources, implementation of medicinal chemistry and biology and create a leading mitochondrial drug discovery and development platform for the future." — Dennis I. Goldberg, Ph.D., Chief Executive Officer at Luciole Pharmaceuticals.
"Our collaboration with Luciole, to accelerate the discovery of novel therapeutics to address various neurodegenerative disorders, will further complement Cyclica's overall mandate, to build the biotech pipeline of the future by embracing the complexity of disease. This partnership will foster Luciole's strong expertise in mitochondrial DNA repair and Cyclica's multi-objective design platform and complementary program offerings to address therapeutic gaps for patients suffering from neurodegenerative diseases.'' — Dr. Vern De Biasi, Chief Partnership Officer.